Geng Liang-Quan

We don’t have enough information about this author to calculate their statistics. If you think this is an error let us know.
Learn More
Background: Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is an effective treatment for severe aplastic anemia (SAA). However, graft failure and graft-versus-host disease (GVHD) are major causes of the early morbidity in Allo-HSCT. Methods: To reduce graft failure and GVHD, we treated fifteen patients with SAA using highdose of HSCT with(More)
  • 1